Rezdiffra (Resmetirom) Cost in Hawaii 2026

What Is Rezdiffra and Why Does It Cost So Much?

Rezdiffra (resmetirom) is the first drug approved by the FDA specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (stages F2 and F3). The FDA granted accelerated approval on March 14, 2024, based on surrogate endpoints: NASH resolution and fibrosis improvement on liver biopsy at 52 weeks 1.

Madrigal Pharmaceuticals set the wholesale acquisition cost (WAC) at approximately $3,500 per month at launch. That figure reflects a narrow approved population, a decade-plus of clinical development, and the absence of generic competition. No generic or biosimilar resmetirom exists in 2026.

How Resmetirom Works

Resmetirom selectively activates thyroid hormone receptor-beta (THR-beta) in the liver. THR-beta activation increases mitochondrial fatty acid oxidation, reduces hepatic lipid accumulation, and lowers LDL cholesterol and triglycerides 2. The selectivity for THR-beta over THR-alpha is what limits cardiac and bone side effects that plagued earlier thyroid hormone analogs.

The MAESTRO-NASH Trial Results

The MAESTRO-NASH trial (N=966) published in the New England Journal of Medicine in 2024 provided the key data for FDA approval. At 52 weeks, NASH resolution occurred in 29.9% of patients on resmetirom 100 mg versus 9.7% on placebo (P<0.001) 2. Fibrosis improvement of at least one stage without NASH worsening occurred in 25.9% on resmetirom 100 mg versus 14.2% on placebo (P<0.001) 2.

The FDA's accelerated approval pathway means confirmatory trials are ongoing. Madrigal's MAESTRO-NASH OUTCOMES trial is tracking hard cardiovascular and liver endpoints through 2027 3.

Who Qualifies for the Approved Indication

Per the FDA label, Rezdiffra is indicated for adults with MASH and liver fibrosis stages F2 or F3, used alongside a reduced-calorie diet and increased physical activity 1. Stage F4 (cirrhosis) is not an approved indication. Prescribers in Hawaii must confirm fibrosis staging, typically through liver biopsy or validated non-invasive markers (FIB-4, liver elastography), before initiating therapy 4.

Rezdiffra Cash Price in Hawaii in 2026

The average cash-pay price at retail pharmacies across Hawaii in 2026 is $3,500 per month, matching the WAC. There is no meaningful price variation between Hawaii retail chains and the national average because Madrigal has not offered pharmacy-level competitive discounts outside its patient assistance infrastructure.

Why Hawaii's Price Matches the National WAC

Hawaii does not have a state-level prescription drug price negotiation program for commercially purchased drugs. The state's Med-QUEST Medicaid program has simply excluded resmetirom from its formulary rather than negotiating a rebated price. Without formulary placement, there is no confidential rebate that would lower effective cost to payers or patients in Hawaii.

Specialty Pharmacy Dispensing

Rezdiffra is dispensed exclusively through specialty pharmacies. In Hawaii, CVS Specialty, Accredo (Express Scripts), and Walgreens Specialty are the primary dispensing channels 1. Patients on neighbor islands (Maui, Kauai, Hawaii Island, Molokai, Lanai) receive medication by mail from Honolulu-based or mainland specialty pharmacy hubs. Shipping times of 2 to 5 business days should be factored into refill planning.

Price Per Day and Per Pill

At $3,500 per 30-day supply, the math is $116.67 per day or $116.67 per tablet. Rezdiffra is dispensed as 80 mg or 100 mg tablets. The dose is one tablet daily, so there is no dose-splitting option that would lower per-day cost.

Hawaii Medicaid (Med-QUEST) Coverage for Rezdiffra

Hawaii Medicaid, administered through the Med-QUEST Division, does not cover Rezdiffra (resmetirom) as of 2026. The drug is absent from all five Med-QUEST managed care organization (MCO) formularies: AlohaCare, HMSA (Quest Integration), Kaiser Permanente Hawaii, 'Ohana Health Plan, and UnitedHealthcare Community Plan 5.

Why Med-QUEST Has Not Covered Rezdiffra

Three factors explain the exclusion. First, accelerated approval means the FDA's confirmatory outcomes trial data are not yet available, giving payers a clinical uncertainty argument. Second, the budget impact is substantial: MASH affects an estimated 1.5% to 6.5% of U.S. Adults with obesity or type 2 diabetes 6, and Hawaii's Med-QUEST enrollment exceeds 430,000 members. Third, existing AASLD (American Association for the Study of Liver Diseases) guidelines do not yet classify pharmacotherapy as a standard of care, giving formulary committees a guideline-gap justification 7.

Appealing a Medicaid Denial in Hawaii

Patients can file a formal grievance with their Med-QUEST MCO within 90 days of a denial. If the MCO upholds the denial, the patient may request a State Fair Hearing through the Hawaii Department of Human Services. Success rates for experimental or non-formulary drug appeals are low without peer-reviewed data supporting medical necessity for the specific patient's fibrosis stage and comorbidities.

Medicare Part D in Hawaii

Medicare Part D plans in Hawaii assess resmetirom individually by plan. As of 2025 plan year data, most Part D formularies place resmetirom on Tier 5 (specialty tier) with cost-sharing between 25% and 33% after deductible, producing a monthly out-of-pocket cost of $875 to $1,155 before the $2,000 annual out-of-pocket cap introduced by the Inflation Reduction Act 8. After reaching the $2,000 cap, Part D enrollees pay $0 for the remainder of the plan year.

Commercial Insurance Coverage in Hawaii

Most commercial insurers operating in Hawaii, including HMSA (a Blue Cross Blue Shield affiliate), Kaiser Permanente Hawaii, UHA Health Insurance, and AlohaCare commercial plans, have issued coverage policies for Rezdiffra with prior authorization (PA) requirements.

Typical Prior Authorization Criteria

Insurers in Hawaii generally require all of the following before approving coverage 1:

• Confirmed MASH diagnosis on liver biopsy or equivalent non-invasive test
• Fibrosis stage F2 or F3 documented within the prior 24 months
• BMI at or above 27 kg/m² (matching the MAESTRO-NASH enrollment criteria)
• Absence of decompensated cirrhosis (Child-Pugh B or C)
• Concurrent lifestyle intervention documentation
• Prescriber attestation from a gastroenterologist, hepatologist, or endocrinologist

What to Do If Your PA Is Denied

A first-level PA denial is not a final answer. Physicians can submit a peer-to-peer review request, usually within 14 days of the denial letter. Attaching MAESTRO-NASH trial data 2 directly to the appeal and citing the patient's specific FIB-4 score and elastography result strengthens the clinical necessity argument. If the peer-to-peer fails, an external independent review is the next step under Hawaii's insurance appeal rights (Hawaii Revised Statutes Chapter 432E).

Employer Self-Funded Plans

Roughly 60% of commercially insured Hawaiians are covered under ERISA-governed self-funded employer plans. These plans are not bound by Hawaii state insurance mandates, so coverage varies by employer. Contacting the plan's pharmacy benefit manager (PBM) directly and requesting a formulary exception with clinical documentation is the most direct path.

Madrigal Pharmaceuticals Patient Savings Programs in Hawaii

Madrigal offers two programs that can meaningfully reduce cost for Hawaii patients who do not have Medicaid.

Rezdiffra Co-Pay Savings Card

Commercially insured patients who meet eligibility criteria may pay as little as $0 per month through Madrigal's co-pay savings card, with a maximum benefit of $26,000 per calendar year 9. Patients must have commercial insurance (Medicare and Medicaid patients are excluded) and must be U.S. Residents. Hawaii residents qualify. Enrollment is available through Madrigal's patient support program, Madrigal One Source.

Madrigal Patient Assistance Program

Uninsured or underinsured patients who meet income criteria (generally household income at or below 600% of the federal poverty level) may qualify for free medication through Madrigal's patient assistance program. Applications require documentation of insurance status and income. Processing typically takes 2 to 4 weeks.

HealthRX Hawaii Cost Navigation Framework for Rezdiffra

The table below summarizes the most likely cost outcome by insurance status for Hawaii patients in 2026.

| Insurance Status | Likely Monthly Cost | Key Action | |---|---|---| | Commercial insurance (approved PA) | $0 to $150 with co-pay card | Enroll in Madrigal One Source | | Commercial insurance (denied PA) | $3,500 until appeal succeeds | File peer-to-peer within 14 days | | Medicare Part D (after $2,000 OOP cap) | $0 | Confirm cap date with Part D plan | | Medicare Part D (before cap) | $875 to $1,155/month | Apply for extra help (LIS) | | Hawaii Med-QUEST Medicaid | Not covered | Appeal or seek 503A compounding | | Uninsured, income <600% FPL | $0 through PAP | Apply via Madrigal One Source | | Uninsured, income above threshold | $3,500 or compounded option | See 503A section below |

Compounded Resmetirom in Hawaii: Legality and Cost

Compounded resmetirom is available through licensed 503A compounding pharmacies in Hawaii. The legal basis is the FDA's current classification: resmetirom is not on the FDA's Demonstrably Difficult to Compound (DDTC) list, and it is not a biologic, so it is not categorically prohibited for traditional compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act 10.

What 503A Means in Hawaii

A 503A pharmacy is a state-licensed, patient-specific compounding pharmacy operating under a valid prescription from a licensed prescriber. Hawaii's pharmacy board (Hawaii Pharmacy and Poisons Advisory Committee) permits 503A compounding. The pharmacy must compound resmetirom from a U.S.-sourced active pharmaceutical ingredient (API) that meets USP standards 10.

503B outsourcing facilities (which compound without a patient-specific prescription) may NOT legally compound resmetirom while it remains a commercially available, FDA-approved drug. Only 503A pharmacies with a valid prescription can dispense it legally 10.

Cost of Compounded Resmetirom in Hawaii

Compounded resmetirom costs vary by pharmacy and formulation, but pricing from Hawaii-accessible 503A pharmacies in 2026 ranges from $150 to $400 per month for a 30-day supply, compared to $3,500 for brand Rezdiffra. Some telehealth platforms that serve Hawaii quote costs near $0 per month for the first few months during introductory promotions, though base pricing typically settles between $200 and $350 monthly.

Clinical Caveat on Compounded Resmetirom

Compounded resmetirom has not been tested in any Phase 3 trial. The MAESTRO-NASH trial used only Madrigal's proprietary tablet formulation 2. Bioavailability of a compounded oral capsule or suspension may differ. Patients and prescribers should document informed consent acknowledging this distinction. The FDA has noted generally that compounded versions of approved drugs lack the clinical data supporting approval 10.

Telehealth Prescribing of Rezdiffra in Hawaii

Hawaii permits telehealth prescribing of controlled substances and non-controlled prescription drugs under Hawaii Revised Statutes Section 453-1.3 and the Hawaii Medical Board's telehealth rules 11. Resmetirom is not a controlled substance, so prescribing it via telehealth in Hawaii requires only a valid prescriber-patient relationship established through a synchronous audio-visual encounter.

What a Telehealth Rezdiffra Visit Looks Like

A Hawaii patient seeking resmetirom through a telehealth platform (including HealthRX) should expect:

• A synchronous video visit with a licensed hepatologist, gastroenterologist, or internist
• Review of liver imaging (ultrasound, MRI-PDFF, or FibroScan elastography result)
• Review of labs: ALT, AST, FIB-4 score, lipid panel, TSH, and a pregnancy test for women of childbearing potential (resmetirom is contraindicated in pregnancy per the FDA label 1)
• Discussion of goals, expected timeline, and monitoring schedule
• Electronic prescription sent to a specialty or 503A pharmacy of the patient's choice

Neighbor island residents (Maui, Kauai, Big Island) benefit most from telehealth access, since hepatology specialists are concentrated on Oahu.

Monitoring Requirements After Starting Rezdiffra

The FDA label requires liver enzyme monitoring (ALT, AST) at baseline, at 12 weeks, and every 6 months thereafter 1. If ALT exceeds 3x the upper limit of normal and is accompanied by symptoms or jaundice, the drug must be discontinued. Telehealth prescribers coordinate with local labs in Hawaii (Quest Diagnostics and Clinical Laboratories of Hawaii have island-wide draw sites) to fulfill these monitoring requirements 12.

Clinical Context: MASH Prevalence and Treatment Gap in Hawaii

MASH (formerly NASH) affects an estimated 5 to 6.5 million U.S. Adults, with higher prevalence among individuals with obesity, type 2 diabetes, and metabolic syndrome 6. Hawaii's population has elevated rates of type 2 diabetes and obesity relative to the mainland U.S. Average, particularly among Native Hawaiian and Pacific Islander communities, putting a disproportionate share of Hawaii residents at risk for progressive MASH 13.

Fibrosis Staging Matters for Coverage and Prognosis

Not every MASH patient qualifies for Rezdiffra. The FDA approval covers only F2 and F3 fibrosis. Patients with F0 or F1 fibrosis do not have an FDA-approved pharmacotherapy option and are not eligible for insurance coverage of resmetirom. Patients with F4 (cirrhosis) are also outside the approved indication. The Baveno VII consensus 14 recommends FIB-4 as the initial non-invasive triage test, with a cutoff below 1.30 suggesting low risk (F0-F1) and above 2.67 suggesting advanced fibrosis, with liver stiffness measurement recommended for intermediate values.

LDL-Lowering Effect as a Secondary Benefit

Beyond fibrosis endpoints, MAESTRO-NASH showed resmetirom 100 mg reduced LDL cholesterol by 16.3% and triglycerides by 22.6% at 52 weeks versus placebo 2. For Hawaii patients who have concurrent dyslipidemia, this secondary lipid benefit may strengthen the clinical case to insurers during PA appeals, since cardiovascular risk reduction is a documented secondary effect.

How to Find a Rezdiffra Prescriber in Hawaii

Hepatologists and gastroenterologists who manage MASH are concentrated at The Queen's Medical Center and Straub Medical Center on Oahu. The University of Hawaii at Manoa John A. Burns School of Medicine operates a liver disease program at Queen's that follows AASLD practice guidance 7. On neighbor islands, internal medicine physicians with hepatology training or telemedicine consult access are the most accessible option.

The American Association for the Study of Liver Diseases (AASLD) 2023 guidance states: "Patients with MASH and significant fibrosis (F2-F3) represent the population most likely to benefit from pharmacologic intervention, given the rate of fibrosis progression and associated liver-related mortality risk" 7.

HealthRX connects Hawaii patients with board-certified prescribers via telehealth. After a video consult, electronic prescriptions route directly to a specialty pharmacy or a licensed 503A compounding pharmacy, depending on the patient's insurance and cost preference.

Rezdiffra Drug Interactions and Contraindications Relevant to Hawaii Prescribers

Key Drug Interactions

Resmetirom is a substrate of CYP3A4 and P-glycoprotein (P-gp). Strong CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit in large quantities) increase resmetirom plasma exposure. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce exposure significantly 1. Concurrent statin use does not require dose adjustment, but the FDA label recommends monitoring for myopathy since resmetirom inhibits OATP1B1/1B3 transporters, increasing statin plasma levels 1.

Contraindications

The FDA label lists two absolute contraindications: pregnancy (Category X equivalent, based on animal data showing embryotoxicity) and co-administration with moderate or strong CYP3A4 inhibitors in the setting of hepatic impairment 1. Women of childbearing potential in Hawaii must use effective contraception during treatment and for two weeks after the last dose 1.